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Several studies have shown that notoginsenoides improve diastolic function in hypertensive subjects,
induce the fibrinolytic system in in vitro models and act as antiproliferative agents on vessel leiomyocytes.
Our aim was to evaluate their effect on fibrinogen and lipid plasma levels compared with a well-known
HMGCoA reductase inhibitor. Seventy Wistar male adult rats on a fat-enriched diet were treated orally
with P. notoginseng pulverized root (43 mg/kg/day or 86 mg/kg/day; 20 animals per group), fluvastatin
(3 mg/kg/day; 20 animals) or physiological saline (5 mL/kg/day; 10 animals). The ten rats on a normo-
caloric diet were also treated with 5 mL/kg/day of physiological saline. After a 28-day treatment, the rats
were killed and their blood analysed with standard procedures. Treatment with 43 mg/kg/day of P. noto-
ginseng or 3 mg/kg/day of fluvastatin showed similar activity in decreasing total cholesterol (23.70%,
19.29%, respectively) and triglycerides (21.59%, 18.55%). The most evident effect of P. notoginseng
was the reduction of fibrinogenaemia in treated rats compared with the control values (38.10%;
p 0.001), no dose-relationship being shown in this effect. Moreover, no significant variation in HDL
cholesterol and glucose levels was observed nor did relevant behavioural changes occur in association
with the root intake. Besides a moderate, non dose-related decrease in the plasma lipid levels, P. notogin-
seng appeared to induce a significant reduction in the rat fibrinogenaemia. Copyright  2003 John
Wiley & Sons, Ltd.
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INTRODUCTION
The potential use of Arialiaceae roots in cardiovascular
disease prevention was first recognized by Japanese
authors 20 years ago. In fact, Panax ginseng (Renshen)
administration induced a decrease in low density
lipoprotein cholesterol (LDL-C) triglycerides (TG)
plasma and liver levels, as well as an increase in the
high density lipoprotein cholesterol (HDL-C) plasma
levels and a reduction of platelet adhesiveness in both rats
(Yamamoto et al., 1983a) and hyperlipidaemic patients
(Yamamoto et al., 1983b; Punnonen and Lukola, 1984).
The proposed mechanisms of action were the following:
an increase in faecal fat excretion, a decrease in the
activities of -hydroxy--methylglutaryl-CoA reductase,
acyl-coenzyme-A-cholesterol acyltransferase and cho-
lesteryl ester transfer protein (Qureshi et al., 1983;
Yamamoto et al., 1983b; Punnonen and Lukda, 1984;
Kwon et al., 1996; Kwon et al., 1999).
Panax notoginseng (Burk.) F. H. Chen (Sanqi) is a
root, similar to the more well-known and studied P.
ginseng (Ngan et al., 1999). All the Arialiaceae of the
ginseng group have a similar composition, even if the
chemical constituents have a different concentration,
specificity and activity (Bruneton, 1999). Recent studies
demonstrated various specific pharmacological actions of
notoginsenoides, especially on the cardiovascular sys-
tem. The chronic administration of P. notoginseng with
the ACE-inhibitor captopril improved the left ventricular
diastolic function in hypertensive patients compared with
treatment with captopril alone; this effect was partially
related to an antagonism to selective Ca receptor
operating channels (Feng et al., 1999). Among the
haemorheological parameters, notoginsenoides appeared
to increase the synthesis of the tissue-type plasminogen
activator and to decrease the activity of plasminogen
activator inhibitor-1 in cultured human endothelial and
vascular smooth muscle cells from different vascular
regions (Zhang et al., 1997). Moreover, a 10-day oral
administration of P. notoginseng increased prostacyclin
synthesis in the carotid artery and decreased thrombox-
ane A2 synthesis in blood platelets; at the end of the
experiment, aortic atherosclerotic plaque development
was reduced (Shi et al., 1990). In a previous study we
evaluated the adaptogenic properties of the root (Cicero
et al., 2000). The aim of this study was to evaluate the
effects of orally administered P. notoginseng (43 mg/kg
and 86 mg/kg in a volume of 5 mL/kg) on plasma lipid
levels and fibrinogenaemia in rats on a high-fat diet.
MATERIALS AND METHODS
Eighty adult male Wistar rats (Harlan Italy, Correzzana,
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Milan, Italy) weighing 240 20 g (3 months old on
arrival) were used and housed 1 per cage in a
temperature- (22° 1C°) and humidity- (60%) con-
trolled environment. The light/dark cycle was the natural
one (the light phase of the cycle beginning at 6 a.m.). The
animals were divided into two groups: ten rats (NC:
normal diet controls) had free access to standard rat food
in pellets (MIL, Morini, S. Polo D’Enza, Reggio
nell’Emilia, Italy), 70 animals were fed with a high-fat
diet containing 19% proteins and 25.5% lipids (10%
cholesterol). Water was available ad libitum. This dietary
regimen was adopted throughout the experiment. Hous-
ing conditions and experiments were in accordance with
the European Community regulations on the care and use
of animals for scientific purposes (CEE Council 86/609,
included in the Italian writ DL 27/01/92 N. 116). The rats
were acclimatized to our housing conditions for at least 1
week before being used.
Drugs and treatment. Rats were orally treated through a
gastric tube for 28 days consecutively. The rats on the fat
diet were divided into four subgroups: ten were treated
with 5 mL/kg/day of saline (FC: fat diet controls), 20
were given 3 mg/kg/day of fluvastatin (FL: fluvastatin),
20 received 43 mg/kg/day of high quality P. notoginseng
pulverized root (Ng) (Yunnan Medicines & Health
Products Corp., Yunnan, R. P. China) and 20:
86 mg/kg/day of P. notoginseng (NG). The NC animals
were also treated with 5 mL/kg/day of saline solution. At
the end of the experiment, the animals were fasted
overnight and killed under ether anaesthesia. Blood was
collected by heart puncture. Plasma samples were stored
at 20°C before being used for analysis.
Laboratory analysis. Lipid levels [total cholesterol
(TC), triglycerides (TG) and high density lipoprotein
cholesterol (HDL-C)] were analysed on plasma samples
by enzymatic-colorimetric methods according to stan-
dard laboratory techniques. The concentration of LDL
cholesterol (LDL-C) was estimated through the Friede-
wald formula: LDL-C = TC  (TG/5HDL-C) for TG
value 400 mg/dL. Glycaemia was also determined by
the enzymatic-colorimetric method, as described by
Gaddi et al. (2001). Fibrinogen levels were measured in
duplicate using the Clauss method (Data-Fi Fibrinogen
determination Kit, Dade County, FL) (Clauss, 1957).
Microstructural analysis of unconditioned behaviour.
The test was carried out to detect any possible P.
notoginseng-induced behavioural changes. Thirty min-
utes after the treatment, the observation started by
keeping the animals in their individual home cages.
The following parameters were separately registered on a
specific schedule of 1 h periods: number and duration
time dedicated to feeding, drinking, exploring, resting
and grooming. Pre-weighed food pellets were provided at
the beginning of the test and food intake was measured at
the end by weighing the remaining food plus spillage.
During the experiment the rats had free access to water.
Statistical analysis. Data were statistically processed by
the Shapiro–Wilk normality test and analysis of variance
(ANOVA-test) followed by Student’s one-tail t-test
(SPSS 8.0, Windows version, statistical software). A
p = 0.05 significance level was chosen for all statistical
tests (Normann and Streiner, 2000).
RESULTS
Before killing the rats’ mean weight had increased by
20% (301 19 g) with no differences between the NC
and FC animals. This fat diet model produced a
significant increase in TC (F = 77.59, p 0.001), LDL-
C (F = 64.76, p 0.001) and TG (F = 185.12, p 0.001)
plasma levels, with no influence on HDL-C, glucose and
fibrinogen levels ( p 0.05) compared with the NC
values. Treatment with fluvastatin significantly lowered
TC (F = 39.94, p 0.001), LDL-C (F = 9.98, p = 0.005)
and TG (F = 17.99, p 0.001) levels compared with
those of the FC group, as expected by the literature data
(Langtry and Markham, 1999). No relevant differences
were observed in the TC (F = 4.31, p = 0.053), LDL-C
(F = 4.25, p = 0.054) and TG (F = 0.76, p 0.428) levels
between fluvastatin treated rats on a fat diet and controls
on a standard diet. The administration of fluvastatin did
not reduce fibrinogenaemia in comparison with NC and
FC rats.
43 mg/kg/day of P. notoginseng pulverized root
significantly decreased TC (F = 20.84, p 0.001),
LDL-C (F = 19.42, p 0.001) and TG (F = 9.58,
p 0.006) levels compared with the FC group. No
relevant differences between the lower dose P. notogin-
Table 1. Components and chemical analysis of fat diet
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seng treated rats on a fat diet and controls on a standard
diet were observed for TC (F = 0.00, p = 0.987), LDL-C
(F = 0.00, p = 0.975) and TG (F = 0.01, p 0.936) levels.
The Ng treatment reduced fibrinogenaemia compared
with NC (F = 36.60, p 0.001) and FC (F = 51.95,
p 0.001) rats.
86 mg/kg/day of P. notoginseng pulverized root
significantly lowered TC (F = 15.66, p 0.001), LDL-
C (F = 11.93, p = 0.003) and TG (F = 6.14, p 0.023)
levels compared with the FC group. No relevant
differences between the higher dose P. notoginseng
treated rats on a fat diet and controls on a standard diet
were observed concerning TC (F = 4.16, p = 0.056),
LDL-C (F = 0.00, p = 1.000) and TG (F = 4.40,
p = 0.051) levels. The NG treatment decreased fibrino-
genaemia compared with NC (F = 20.12, p 0.001) and
FC (F = 57.51, p 0.001) rats.
No significant difference was found between fluvasta-
tin and Ng treated groups in TC (F = 0.81, p = 0.381),
LDL-C (F = 2.46, p = 0.134) and TG (F = 0.14,
p = 0.713). Unlike fluvastatin, Ng significantly lowered
the fibrinogen level. Similar results were found compar-
ing fluvastatin and NG treated rats. Ng and NG showed
similar activity in reducing TC (F = 1.64, p = 0.217),
LDL-C (F = 3.37, p = 0.083) and TG (F = 1.34,
p = 0.263), while Ng seemed to be more effective in
reducing the fibrinogen level than NG (F = 15.74,
p 0.001).
Changes in TC, LDL-C, TG and fibrinogen plasma
levels are reported in Figs 1 2 3–4. Microstructural
analysis of the spontaneous behaviour revealed that both
doses of orally administered P. notoginseng significantly
increased the exploring time ( p 0.03) while reducing
the grooming ( p 0.001) and resting times ( p 0.03).
Once again, both P. notoginseng doses produced a greater
number of exploring episodes ( p 0.01), and a lower
number of grooming ( p 0.03) and resting episodes
( p 0.05) than the control rats. No significant differ-
ences in the duration and number of the episodes were
observed between the 43 mg/kg and the 86 mg/kg P.
notoginseng-treated rats ( p 0.05). Finally, no signifi-
cant difference was found in either feeding or drinking
behaviour ( p 0.05).
DISCUSSION
The utility of some natural products in the treatment and
prevention of atherosclerosis-related cardiovascular dis-
ease has been rigorously tested on animal and human
models. Currently the non-pharmaceutical aids in
moderate dyslipidaemias are soy bean proteins for
hypercholesterolaemias (Anderson et al., 1995), fish oil
for hypertriglyceridaemias and hypoHDLaemias (GISSI,
1999), rice bran oil for moderate hypercholesterolaemias
and hypertriglyceridaemias (Cicero and Gaddi, 2001).
Recent studies show that high fibrinogen is an emerging
independent risk factor for cardiovascular diseases
(Harjai, 1999). In healthy non-smoking men, its level is
associated with the expression of a more atherogenic
LDL subfraction (small and dense LDL with d 1.044
g/dL), and a lower HDL-C level, in a way that is
independent of body mass index, age and insulin
resistance (Halle et al., 1996). In contrast, the only drugs
that actually demonstrate a lowering effect on this
parameter are the fibrates (bezafibrate, fenofibrate and
ciprofibrate, but not gemfibrozil) that induced a fibrino-
genaemia decrease of 10% to 30% in different
clinical trials (Pazzucconi et al., 1992; Broijersen et al.,
1996). In contrast to fibrates, -hydroxy--methylglu-
taryl-CoA reductase inhibitors (statins) generally induce
only a slight effect on the fibrinogen blood level (Nair et
al., 1998; Jones et al., 1998). However, recent reports
indicate an association between atorvastatin administra-
tion, a very potent lipid lowering agent, and fibrinogen-
aemia increase (ranging from 20% to 50%) in some
treated patients (Wierzbicki et al., 1998; Sinzinger and
Rodrigues, 1999). The aim of our study was to confirm
the decreasing effect of P. notoginseng on plasma lipids
and to evaluate its effect on the fibrinogen plasma levels
in rats fed a new model of a fat diet compared with the
activity of a well-known effective statin (Langtry and
Markham, 1999). We know that, theoretically, we had to
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use a fibrate or pravastatin as a positive control to test the
P. notoginseng efficacy to reduce the fibrinogenaemia,
but we did not expect such a marked effect of the root on
this parameter. The P. notoginseng doses were planned
on the basis of the Traditional Chinese Medicine
prescriptions for the treatment of angina pectoris and
dyslipidaemias. The role of the root components
(flavonoids, saponins, notoginsenoides and others) in
cardiovascular disease management may be due to
different properties: Ca-channel blocking activity,
improvement of diastolic function in hypertensive
patients (Feng et al., 1999), increase in rTPA and
decrease in PAI-1 synthesis in cultured human endothe-
lium cells (Zhang et al., 1997) and correction of an
inbalance between prostacyclin and thromboxane A2 (Shi
et al., 1990). Our data confirm that orally administered P.
notoginseng pulverized root produced a significant, non
dose-related, lipid lowering effect compared with con-
trols and a well-known effective treatment in hyper-
lipidaemic rats. 43 mg/kg/day of P. notoginseng and
3 mg/kg/day of fluvastatin showed a similar activity in
decreasing plasma TC (23.70% and 19.29%, respec-
tively) and TG (21.59% and18.55%) levels, while no
significant change in HDL-C and glucose levels was
observed ( p 0.05). The most important P. notoginseng
effect was the mean reduction in fibrinogenaemia
compared with the control values (38.10%; F = 51.95,
p 0.001). No relevant behavioural modification was
associated with the root intake. Just as all herbal remedies
that consist of a mixture of many compounds, P.
notoginseng root exerts its several pharmacological
actions on different parameters. We suggest that further
molecular studies are needed on the P. notoginseng root
to identify the different components of this root in order
to correlate molecular structure and effects. Since only a
small fraction of the world is plant biodiversity has been
tested for biological activity, it can be assumed that
natural products will continue to offer new leads for
innovative therapeutic agents.
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